Zofran Label Updated Over Safety Concerns
The Food and Drug Administration issued a safety warning for the anti-nausea drug Zofran (ondansetron ) due to the potential risk of abnormal heart rhythm at certain dosages. Preliminary results from a recent clinical study suggests that a 32 mg intravenous dose of Zofran or its generics may affect the electrical activity of the heart, which could cause patients to